Operating Income (Loss) in USD of Gossamer Bio, Inc. from 2017 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Gossamer Bio, Inc. quarterly/annual Operating Income (Loss) history and change rate from 2017 to Q3 2025.
  • Gossamer Bio, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$49,114,000.000, a 44.8% decline year-over-year.
  • Gossamer Bio, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$160,817,000.000, a 121% decline year-over-year.
  • Gossamer Bio, Inc. annual Operating Income (Loss) for 2024 was -$59,919,000.000, a 67.4% increase from 2023.
  • Gossamer Bio, Inc. annual Operating Income (Loss) for 2023 was -$183,759,000.000, a 15.9% increase from 2022.
  • Gossamer Bio, Inc. annual Operating Income (Loss) for 2022 was -$218,593,000.000, a 1.14% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Gossamer Bio, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$160,817,000 -$49,114,000 -$15,195,000 -44.8% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025
Q2 2025 -$145,622,000 -$38,765,000 -$90,852,000 -1.7% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025
Q1 2025 -$54,770,000 -$36,810,000 +$5,149,000 +12.3% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 -$59,919,000 -$36,128,000 +$12,899,000 +26.3% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025
Q3 2024 -$72,818,000 -$33,919,000 +$6,571,000 +16.2% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025
Q2 2024 -$79,389,000 $52,087,000 +$98,387,000 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025
Q1 2024 -$177,776,000 -$41,959,000 +$5,983,000 +12.5% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 -$183,759,000 -$49,027,000 +$5,330,000 +9.8% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025
Q3 2023 -$189,089,000 -$40,490,000 +$15,531,000 +27.7% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 -$204,620,000 -$46,300,000 +$7,572,000 +14.1% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024
Q1 2023 -$212,192,000 -$47,942,000 +$6,401,000 +11.8% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024
Q4 2022 -$218,593,000 -$54,357,000 -$2,696,000 -5.2% 01 Oct 2022 31 Dec 2022 10-K 13 Mar 2025
Q3 2022 -$215,897,000 -$56,021,000 -$357,000 -0.64% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$215,540,000 -$53,872,000 +$1,724,000 +3.1% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023
Q1 2022 -$217,264,000 -$54,343,000 -$1,140,000 -2.1% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023
Q4 2021 -$216,124,000 -$51,661,000 +$8,426,000 +14% 01 Oct 2021 31 Dec 2021 10-K 05 Mar 2024
Q3 2021 -$224,550,000 -$55,664,000 -$2,095,000 -3.9% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022
Q2 2021 -$222,455,000 -$55,596,000 +$9,743,000 +14.9% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022
Q1 2021 -$232,198,000 -$53,203,000 +$1,764,000 +3.2% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022
Q4 2020 -$233,962,000 -$60,087,000 -$4,300,000 -7.7% 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2023
Q3 2020 -$229,662,000 -$53,569,000 -$3,583,000 -7.2% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021
Q2 2020 -$226,079,000 -$65,339,000 -$18,990,000 -41% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021
Q1 2020 -$207,089,000 -$54,967,000 -$20,950,000 -61.6% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021
Q4 2019 -$186,139,000 -$55,787,000 -$15,980,000 -40.1% 01 Oct 2019 31 Dec 2019 10-K 24 Mar 2020
Q3 2019 -$170,159,000 -$49,986,000 +$38,000 +0.08% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020
Q2 2019 -$170,197,000 -$46,349,000 -$13,313,000 -40.3% 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020
Q1 2019 -$156,884,000 -$34,017,000 -$7,891,000 -30.2% 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020
Q4 2018 -$148,993,000 -$39,807,000 01 Oct 2018 31 Dec 2018 10-K 24 Mar 2020
Q3 2018 -$50,024,000 01 Jul 2018 30 Sep 2018 10-K 24 Mar 2020
Q2 2018 -$33,036,000 01 Apr 2018 30 Jun 2018 10-K 24 Mar 2020
Q1 2018 -$26,126,000 01 Jan 2018 31 Mar 2018 10-K 24 Mar 2020

Gossamer Bio, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$59,919,000 +$123,840,000 +67.4% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025
2023 -$183,759,000 +$34,834,000 +15.9% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025
2022 -$218,593,000 -$2,469,000 -1.1% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2025
2021 -$216,124,000 +$17,838,000 +7.6% 01 Jan 2021 31 Dec 2021 10-K 05 Mar 2024
2020 -$233,962,000 -$47,823,000 -25.7% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2023
2019 -$186,139,000 -$37,146,000 -24.9% 01 Jan 2019 31 Dec 2019 10-K 03 Mar 2022
2018 -$148,993,000 -$142,340,000 -21.4% 01 Jan 2018 31 Dec 2018 10-K 26 Feb 2021
2017 -$6,653,000 01 Jan 2017 31 Dec 2017 10-K 24 Mar 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.